Edition:
United Kingdom

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

10.84USD
8:59pm GMT
Change (% chg)

$-0.36 (-3.21%)
Prev Close
$11.20
Open
$11.21
Day's High
$11.23
Day's Low
$10.82
Volume
1,753
Avg. Vol
37,752
52-wk High
$15.75
52-wk Low
$5.48

Chart for

About

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein... (more)

Overall

Beta: --
Market Cap(Mil.): $70.42
Shares Outstanding(Mil.): 9.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials

* KALVISTA PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2019 FOR KVD001

05 Jan 2018

BRIEF-Kalvista Pharmaceuticals Reports Q2 Loss Per Share $0.50

* KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS

14 Dec 2017

BRIEF-Ra Capital Management says it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 mln

* Ra Capital Management says ‍​on Oct 12, it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 million - SEC Filing

13 Nov 2017

BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍​

* Longwood Fund II Lp reports 8.7 pct stake in Kalvista Pharmaceuticals Inc as of Oct 12 - sec filing‍​ Source text - http://bit.ly/2xTHJJO Further company coverage:

20 Oct 2017

BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck

* Kalvista Pharmaceuticals announces collaboration with Merck

10 Oct 2017

BRIEF-KalVista Pharmaceuticals reports Q1 loss per share of $0.51

* KalVista pharmaceuticals reports fiscal first quarter results

14 Sep 2017

Earnings vs. Estimates